CLAIMS

1. Use of an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6) in the manufacture of a medicament for treating multiple myeloma in an individual, wherein the medicament is to be administered with pomalidomide and dexamethasone,

wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg, the pomalidomide is to be administered at a dose of 4 mg, and the dexamethasone is to be administered at a dose of 40 mg individuals under 75 years of age, or the dexamethasone is to be administered at a dose of 20 mg to individuals 75 years of age or older,

wherein the individual has one or more of: chronic obstructive pulmonary disorder (COPD), asthma, and bronchospasms,

wherein the individual received at least two prior therapies for multiple myeloma,

wherein at least one of the at least two prior therapies for multiple myeloma was lenalidomide and at least one of the two prior therapies was a proteasome inhibitor, and

wherein the treatment extends progression free survival (PFS) and/or overall survival (OS) of the individual.

2. Use of an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid

sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6) in the manufacture of a medicament for reversing renal function impairment in an individual with multiple myeloma, wherein the medicament is to be administered with pomalidomide and dexamethasone,

wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg, the pomalidomide is to be administered at a dose of 4 mg, and the dexamethasone is to be administered at a dose of 40 mg individuals under 75 years of age, or the dexamethasone is to be administered at a dose of 20 mg to individuals 75 years of age or older,

wherein the individual has received at least two prior therapies for multiple myeloma, and

wherein at least one of the at least two prior therapies for multiple myeloma was lenalidomide and at least one of the at least two prior therapies was a proteasome inhibitor.

3. The use according to claim 1 or 2, wherein the at least two prior therapies did not include treatment with an anti-CD38 antibody and/or treatment with pomalidomide.

4. The use according to any one of claims 1-3, wherein the individual did not respond to at least one of the at least two prior therapies, or wherein the individual relapsed after at least one of the at least two prior therapies, or wherein the individual experienced disease progression during or after the treatment with at least one of the two prior therapies.

5. The use according to any one of claims 2-4, wherein the individual with multiple myeloma is selected for the administration based on the individual having renal impairment.

6. The use according to claim 5, wherein the individual has an estimated glomerular filtration rate (eGFR) less than about 60 mL/min/1.73m^2.

7. The use according to any one of claims 2-6, wherein the treatment extends progression free survival (PFS) of the individual.

8. The use according to any one of claims 2-7, wherein the treatment extends overall survival (OS) of the individual.

9. The use according to any one of claims 1, 3-4, and 7, wherein the treatment extends the PFS of the individual by at least about 9 months.

10. The use according to any one of claims 1, 3-4, and 7, wherein the treatment extends the PFS of the individual by at least about 4.5 months relative to an individual having multiple myeloma who received a treatment comprising pomalidomide and dexamethasone without the anti-CD38 antibody.

11. The use according to any one of claims 1, 3-4, and 9-10, wherein the treatment reverses renal function impairment.

12. The use according to any one of claims 1-11, wherein the individual achieves a response to the treatment faster than an individual having multiple myeloma who received a treatment comprising pomalidomide and dexamethasone without the anti-CD38 antibody.

13. The use according to any one of claims 2-11, wherein the individual achieves a renal response to the treatment faster than an individual having multiple myeloma who received a treatment comprising pomalidomide and dexamethasone without the anti-CD38 antibody.

14. The use according to claim 13, wherein the renal response is a complete renal response.

15. The use according to claim 14, wherein the complete renal response is sustained for at least 60 days.

16. The use according to any one of claims 1-15, wherein the anti-CD38 antibody comprises a heavy chain variable region (V_H) comprising an amino acid sequence of SEQ ID NO: 7 and a light chain variable region (V_L) comprising an amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 9.

17. The use according to any one of claims 1-16, wherein the anti-CD38 antibody is isatuximab.

18. The use according to any one of claims 1-17, wherein the anti-CD38 antibody, the pomalidomide, and the dexamethasone are to be administered in a first 28-day cycle,

wherein the anti-CD38 antibody is to be administered on Days 1, 8, 15, and 22 of the first 28-day cycle, the pomalidomide is to be administered on each of Days 1-21 of the first 28-day cycle, and the dexamethasone is to be administered on Days 1, 8, 15, and 22 of the first 28-day cycle.

19. The use according to claim 18, wherein the anti-CD38 antibody, the pomalidomide, and the dexamethasone are to be further administered in one or more 28-day cycles following the first 28-day cycle,

wherein the anti-CD38 antibody is to be administered on Days 1 and 15 of the one or more 28-day cycles following the first 28-day cycle, the pomalidomide is to be administered on each of Days 1-21 of the one or more 28-day cycles following the first 28-day cycle, and the dexamethasone is to be administered on Days 1, 8, 15, and 22 of the one or more 28-day cycles following the first 28-day cycle.

20. The use according to claim 18 or 19, wherein the pomalidomide and the dexamethasone are to be administered prior to the anti-CD38 antibody on Day 1 of the first 28-day cycle.

21. The use according to any one of claims 18-20, wherein the dexamethasone is to be administered prior to the anti-CD38 antibody on Days 8, 15, and 22 of the first 28 -day cycle, and wherein the anti-CD38 antibody is to be administered prior to the pomalidomide on Days 8 and 15 of the first 28-day cycle.

22. The use according to any one of claims 18-21, wherein the pomalidomide and the dexamethasone are to be administered prior to the anti-CD38 antibody on Day 1 of the one or more 28-day cycles following the first 28-day cycle.

23. The use according to any one of claims 18-22, wherein the dexamethasone is to be administered prior to the anti-CD38 antibody, and wherein the anti-CD38 antibody is to be administered prior to the pomalidomide on Day 15 of the one or more 28-day cycles following the first 28-day cycle.

24. The use according to any one of claims 1-17, wherein the anti-CD38 antibody, the pomalidomide, and the dexamethasone are to be administered in a first 28-day cycle,

wherein the anti-CD38 antibody is to be administered once every week of the first 28-day cycle, the pomalidomide is to be administered for 21 days of the first 28-day cycle, and the dexamethasone is to be administered once every week of the first 28-day cycle.

25. The use according to claim 24, wherein the anti-CD38 antibody, the pomalidomide, and the dexamethasone are to be further administered in one or more 28-day cycles following the first 28-day cycle,

wherein the anti-CD38 antibody is to be administered once every other week of the one or more 28-day cycles following the first 28-day cycle, the

pomalidomide is to be administered for 21 days of the one or more 28-day cycles following the first 28-day cycle, and the dexamethasone is to be administered once every week of the one or more 28-day cycles following the first 28-day cycle.

26. The use according to claim 24 or 25, wherein the pomalidomide and the dexamethasone are to be administered prior to the anti-CD38 antibody in the first 28-day cycle.

27. The use according to any one of claims 24-26, wherein the dexamethasone is to be administered prior to the anti-CD38 antibody and wherein the anti-CD38 antibody is to be administered prior to the pomalidomide in the first 28-day cycle.

28. The use according to any one of claims 24-27, wherein the pomalidomide and the dexamethasone are to be administered prior to the anti-CD38 antibody in the one or more 28-day cycles following the first 28-day cycle.

29. The use according to any one of claims 24-28, wherein the dexamethasone is to be administered prior to the anti-CD38 antibody, and wherein the anti-CD38 antibody is to be administered prior to the pomalidomide in the one or more 28-day cycles following the first 28-day cycle.

30. The use according to any one of claims 1-29, wherein the anti-CD38 antibody is to be administered intravenously.

31. The use according to any one of claims 1-30, wherein the pomalidomide is to be administered orally.

32. The use according to any one of claims 1-31, wherein the dexamethasone is to be administered orally.

33. The use according to any one of claims 1-31, wherein the dexamethasone is to be administered intravenously.

34. The use according to any one of claims 1-33, wherein the individual was refractory to the most recent prior therapy for multiple myeloma.

35. The use according to claim 34, wherein the most recent prior therapy was lenalidomide.

36. The use according to claim 34, wherein the most recent prior therapy was a proteasome inhibitor.

37. The use according to any one of claims 1-36, wherein the proteasome inhibitor is selected from the group consisting of: bortezomib, carfilzomib, and ixazomib.

38. The use according to any one of claims 1-37, wherein the lenalidomide and the proteasome inhibitor were administered in combination.

39. The use according to any one of claims 2-38, wherein the individual has chronic obstructive pulmonary disorder (COPD).

40. The use according to any one of claims 2-39, wherein the individual has asthma.

41. The use according to any one of claims 2-40, wherein the individual has bronchospams.

42. The use according to any one of claims 1-41, wherein the individual has one or more cytogenetic abnormalities selected from the group consisting of: del(17p), t(4;14), and t(14;16).

43. The use according to any one of claims 1-42, wherein the individual is at least 65 but less than 75 years of age.

44. The use according to any one of claims 1-42, wherein the individual is 75 years of age or older.

45. The use according to any one of claims 1-44, wherein the individual has received at least three prior therapies for multiple myeloma.

46. The use according to any one of claims 1-45, wherein the individual is East Asian.

47. The use according to any one of claims 1-46, wherein the individual is Stage III according to the International Staging System (ISS).

48. The use according to any one of claims 1-47, wherein the individual is Stage III according to the Revised International Staging System (R-ISS).

49. The use according to any one of claims 1-48, wherein the individual is minimal residual disease (MRD) negative at a threshold of 10^{-4} or less after treatment.

50. The use according to claim 49, wherein the individual is MRD negative at a threshold of 10^{-5} or less after treatment.

51. The use according to claim 50, wherein the individual is MRD negative at a threshold of 10^{-6} or less after treatment.

52. The use according to any of claims 49-51, wherein MRD is assessed via next generation sequencing (NGS).

53. The use according to any of claims 49-52, wherein MRD is assessed via next generation flow cytometry (NGF).

54. A kit comprising an anti-CD38 antibody for use in combination with pomalidomide and dexamethasone for treating an individual having multiple myeloma according to the use according to any one of claims 1-53.